ClinicalTrials.gg
CompletedNCT06830915Updated Feb 19, 2025

Evaluation of Current Practice of Antimicrobial Use and Clinical Outcome in the Management of Pneumonia Among Pediatric Patients Admitted to Jimma Medical Center, Southwest Ethiopia: A Prospective Observational Study

An observational study in Pneumonia and Bacterial, sponsored by Bule Hora University. Completed at 1 site in Ethiopia. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Bule Hora University · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
161
Ages
1 Year to 17 Years
Sex
All
01

Study summary

A prospective observational study design was conducted on children admitted to the pediatric wards of Jimma Medical Center. The study was conducted from February 03, 2022, to June 03, 2022, and patients aged \< 18 years and diagnosed with pneumonia were included. A chart review supplemented by a self-administered questionnaire was used to collect data. Descriptive statistics and binary logistic regressions were performed for data analyses.

Read the detailed description

2.2 Study Design A hospital-based prospective observational study was conducted in children with pneumonia admitted to the pediatric ward of Jimma Medical Center.

2.3 Participant Eligibility and Inclusion All pediatric patients admitted to the pediatric ward of the Jimma Medical Center with a diagnosis of pneumonia during the study period were screened for eligibility criteria. Patients aged less than or equal to 18 years admitted to the pediatric wards of Jimma Medical Center with a suspected or proven pneumonia diagnosis by physician decision on duty during the study period and Patients whose parents gave assent were included in the study. Patients who died before they started antimicrobial, transferred to other facilities and patient lost follow-up were excluded.

2.4 Sample Size and Sampling Technique No sampling technique was applied; instead, all pediatric patients diagnosed with pneumonia that fulfilled illegibility criteria during the study period were recruited in the study. Accordingly, 146 patients were followed and completed data collected.

2.5 Data Collection Instrument and Quality Assurance The data collections instrument (data abstraction format and self-administered questionnaire) was developed by reviewing the literature on antimicrobial use, antimicrobial resistance, and antimicrobial stewardship program guidelines. Training was given for data collectors on the data collection procedure and research objectives. The principal investigator was regularly checking the consistency and completeness of the data and random checks were also being performed.

2.6 Data Processing and Analysis Data was compiled, cleared, coded, and verified for completeness and accuracy before being included in Epi Data Manager version 4.6.2. Double-entry verification was performed and the data was analyzed using statistical software, SPSS version 25.0. Descriptive statistics (mean, frequency, and cross tabulation) were used to describe practice of antimicrobial use. The bivariate logistic regression was performed for clinical outcome and variables with p-values less than 0.25 with outcomes (poor outcome or good outcome) were taken into account for further analysis. Then, the independent predictors were identified by multivariate logistic regression analysis. All statistical tests were detailed; a P value of less than or equal to 0.05 was considered statistically significant.

02

Conditions studied

  • Pneumonia
  • Bacterial

Browse trials for

Keywords

  • Antimicrobial
  • use
  • Current
  • practice
  • Jimma
  • Pneumonia
03

In context

Pneumonia

2,072 studies on the registry are indexed under Pneumonia; 286 are open to participants now.

This study's enrollment of 161 is below the median of 200 across 699 observational studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Bule Hora University is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All pediatric patients admitted to the pediatric ward of the Jimma Medical Center with a diagnosis of pneumonia during the study period were screened for eligibility criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged less than or equal to 18 years admitted to the pediatric wards of Jimma Medical Center with a suspected or proven pneumonia diagnosis by physician decision on duty during the study period and Patients whose parents gave assent were included in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who died before they started antimicrobial, transferred to other facilities and patient lost follow-up were excluded.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
161 participants (actual)
Patient registry
No

Interventions

  • OtherObservation only

    No intervention made

06

What researchers measure

Primary outcomes

  1. Antibiotics use pattern

    Current practice of antimicrobial agents

    Time frame: February 03,2022 to June 03,2022

  2. Clinical outcome

    Clinical treatment outcome(As poor vs good)

    Time frame: February 03,2022 to June 03,2022

07

Study locations

1 site
  • Jimma University
    Jimma, Oromiya +251, Ethiopia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jun 2022, 4 months.

Of 272 non-industry observational studies under Pneumonia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 56. This study's 4 months is below that.

Counting every sponsor, half of 281 studies reached it within 25 months; a quarter within 14 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 17, 2025
StartActual
Feb 3, 2022
Primary completionActual
Jun 3, 2022
CompletionActual
Jun 3, 2022
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830915
Lead sponsor
Bule Hora University
Collaborators
Jimma University
Responsible party
Abduba Wariyo Guyo (Principal investigator, Bule Hora University) — Principal investigator
First posted
Feb 17, 2025
Start date
Feb 3, 2022
Primary completion
Jun 3, 2022
Completion
Jun 3, 2022
Last update
Feb 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion